Prenetics Global LtdPREEarnings & Financial Report
Nasdaq
Prenetics (NASDAQ:PRE) is a health sciences company headquartered in Hong Kong, with a presence in the United States. It focuses on early detection, prevention, and treatment of diseases, particularly cancer.
PRE Q4 2025 Key Financial Metrics
Revenue
$92.4M
Gross Profit
$48.9M
Operating Profit
$-44.9M
Net Profit
N/A
Gross Margin
53.0%
Operating Margin
-48.7%
Net Margin
N/A
YoY Growth
N/A
Financial Flow
Prenetics Global Ltd Q4 2025 Financial Summary
Prenetics Global Ltd reported revenue of $92.4M for Q4 2025, with a net profit of N/A (N/A margin). Cost of goods sold was $43.4M, operating expenses totaled $93.9M.
Key Financial Metrics
| Total Revenue | $92.4M |
|---|---|
| Net Profit | N/A |
| Gross Margin | 53.0% |
| Operating Margin | -48.7% |
| Report Period | Q4 2025 |
Income Statement
| Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|
| Revenue | $17.7M | $23.6M | $92.4M |
| YoY Growth | N/A | N/A | N/A |
Balance Sheet
| Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|
| Assets | $206.2M | N/A | N/A |
| Liabilities | $45.1M | N/A | N/A |
| Equity | $161.2M | N/A | N/A |
Cash Flow
| Q4 2025 | |
|---|---|
| Operating CF | $-22.9M |